ATE72123T1 - Impfstoff fuer die erzeugung einer gegen ein virus schuetzenden immunogenen t-zellen-antwort. - Google Patents

Impfstoff fuer die erzeugung einer gegen ein virus schuetzenden immunogenen t-zellen-antwort.

Info

Publication number
ATE72123T1
ATE72123T1 AT86301223T AT86301223T ATE72123T1 AT E72123 T1 ATE72123 T1 AT E72123T1 AT 86301223 T AT86301223 T AT 86301223T AT 86301223 T AT86301223 T AT 86301223T AT E72123 T1 ATE72123 T1 AT E72123T1
Authority
AT
Austria
Prior art keywords
virus
cell response
vaccine
generating
peptide
Prior art date
Application number
AT86301223T
Other languages
English (en)
Inventor
Ellen Heber-Katz
Bernhard Dietzschold
Original Assignee
Wistar Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wistar Inst filed Critical Wistar Inst
Application granted granted Critical
Publication of ATE72123T1 publication Critical patent/ATE72123T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AT86301223T 1985-04-19 1986-02-20 Impfstoff fuer die erzeugung einer gegen ein virus schuetzenden immunogenen t-zellen-antwort. ATE72123T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72508785A 1985-04-19 1985-04-19
EP19860301223 EP0203676B1 (de) 1985-04-19 1986-02-20 Impfstoff für die Erzeugung einer gegen ein Virus schützenden immunogenen T-Zellen-Antwort

Publications (1)

Publication Number Publication Date
ATE72123T1 true ATE72123T1 (de) 1992-02-15

Family

ID=24913110

Family Applications (1)

Application Number Title Priority Date Filing Date
AT86301223T ATE72123T1 (de) 1985-04-19 1986-02-20 Impfstoff fuer die erzeugung einer gegen ein virus schuetzenden immunogenen t-zellen-antwort.

Country Status (4)

Country Link
EP (1) EP0203676B1 (de)
AT (1) ATE72123T1 (de)
CA (1) CA1265054A (de)
DE (1) DE3683688D1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837249A (en) * 1985-04-19 1998-11-17 The Wistar Institute Method for generating an immunogenic T cell response protective against a virus
DE3937412A1 (de) * 1989-11-10 1991-05-16 Hoechst Ag Synthetische vakzine zur spezifischen induktion zytotoxischer t-lymphozyten
US6024964A (en) * 1985-06-24 2000-02-15 Hoechst Aktiengesellschaft Membrane anchor/active compound conjugate, its preparation and its uses
US6074650A (en) * 1985-06-24 2000-06-13 Hoechst Aktiengesellschaft Membrane anchor/active compound conjugate, its preparation and its uses
LU86736A1 (fr) * 1987-01-15 1988-08-23 Univ Bruxelles Liposomes sensibilises a des molecules antigeniques de parasites intracellulaires,procede pour les preparations et leurs applications comme moyens de diagnostic et comme agents d'immunisation
EP0290246A3 (de) * 1987-05-08 1990-01-31 The Wistar Institute Of Anatomy And Biology Impfstoff zur Erzeugung einer gegen Tollwutvirus schützenden immunogenen T-Zellen-Respons
CA1337115C (en) * 1987-07-30 1995-09-26 Bernhard Dietzschold Vaccination against rabies-related diseases
AU608354B2 (en) * 1987-07-30 1991-03-28 Wistar Institute, The Vaccination against rabies-related viruses
WO1989002277A2 (en) * 1987-08-28 1989-03-23 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
EP0432693A1 (de) * 1989-12-11 1991-06-19 Sumitomo Chemical Company, Limited Für virusinfizierte Zellen cytotoxische Liposomen
US5543389A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization Covalent polar lipid-peptide conjugates for use in salves
US5543390A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5827819A (en) 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US5256641A (en) * 1990-11-01 1993-10-26 State Of Oregon Covalent polar lipid-peptide conjugates for immunological targeting
FR2670787B1 (fr) * 1990-12-18 1995-06-23 Pasteur Institut Lipopeptides inducteurs des lymphocytes t cytotoxiques et utilisation comme vaccins.
US5871746A (en) * 1990-12-18 1999-02-16 Institut National De La Sainte Et De La Recherche Medicale (Inserm) Cytotoxic T lymphocyte-inducing lipopeptides and use as vaccines
US5554728A (en) * 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
EP0596959B1 (de) * 1991-07-26 2000-03-29 Commonwealth Scientific And Industrial Research Organisation System der bereitstellung eines impfstoffes auf peptidbasis, das sein eigenes adjuvans bildet, und seine herstellung
JP2004533421A (ja) 2001-03-27 2004-11-04 バイオミラ，インコーポレイテッド Ｔ１免疫応答とｔ２免疫応答との間で調節するためのワクチン
DE10148065A1 (de) * 2001-09-28 2003-04-17 Max Planck Gesellschaft (Ester)-Lysolecithine in Liposomen
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
TW201204410A (en) 2004-04-01 2012-02-01 Oncothyreon Inc Mucinous glycoprotein (MUC-1) vaccine
JP5364371B2 (ja) 2005-06-28 2013-12-11 オンコセリオン インコーポレイテッド ムチン糖タンパク質（ｍｕｃ−１）ワクチンによって患者を処置する方法
EP2603233A1 (de) 2010-08-12 2013-06-19 AC Immune S.A. Manipulation von impfstoffen
JP6027011B2 (ja) * 2010-10-26 2016-11-16 エーシー イミューン ソシエテ アノニム 疎水性部分によって修飾されたペプチドを含むリポソームベースの構築物
CN105193724A (zh) 2011-02-24 2015-12-30 肿瘤防护公司 含有佐剂的以muc1 为基础的糖脂肽疫苗

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4762708A (en) * 1982-02-18 1988-08-09 University Patents, Inc. Materials and methods for herpes simplex virus vaccination

Also Published As

Publication number Publication date
EP0203676B1 (de) 1992-01-29
EP0203676A3 (en) 1988-03-02
DE3683688D1 (de) 1992-03-12
EP0203676A2 (de) 1986-12-03
CA1265054A (en) 1990-01-30

Similar Documents

Publication Publication Date Title
DE3683688D1 (de) Impfstoff fuer die erzeugung einer gegen ein virus schuetzenden immunogenen t-zellen-antwort.
ES2070866T3 (es) Vacunas recombinantes contra la coccidiosis.
ATE79548T1 (de) Herpes simplex virus subunitimpfstoff.
EP0342860A3 (de) Neues Protein, Sequenze mit enthaltendem Gene, Vektoren, Verfahren zur Herstellung und Verwendung
ZA936970B (en) Anti-feline immunodeficiency virus (FIV) vaccines
GB2324093A (en) Helicobacter pylori bacterioferritin
IT8021972A0 (it) Procedimento per la preparazione di n-fosfonometil glicina.
DK0491628T3 (da) Lipopeptider inducerende cytotoksiske T-lymfocytter og deres anvendelse som vacciner
ES548052A0 (es) Procedimiento para preparar peptidos
BR9710849A (pt) Vacina contendo uma peróxi-redoxina e/ou uma beta-tubulina.
DK0463053T3 (da) Fremstilling og anvendelse af anthelmintiske midler og beskyttende immunogener
NO902352D0 (no) Fremgangsmaate for fremstilling av en vaksine mot dental karies, samt vaksineblandinger for anvendelse som nesedraaper
IT8820117A0 (it) Procedimento per la preparazione di bis(2,2,6,6_tetrametil_4_piperidil)ammina.
EP0179412A3 (de) Antigen-Peptidverbindungen
AU660437B2 (en) Protective plasmodium falciparum hybrid proteins which contain part-sequences of the malaria antigens HRPII and SERP, the preparation and use thereof
DE3884672D1 (de) Ein synthetisches Nonapeptid zur Verwendung als Adjuvant.
DK204588D0 (da) Humane rhinoviruspeptider, fremgangsmaade til deres fremstilling samt vacciner med inhold af saadanne peptider
AU554859B2 (en) Polymerized albumin vaccine
EP0290246A3 (de) Impfstoff zur Erzeugung einer gegen Tollwutvirus schützenden immunogenen T-Zellen-Respons
FR2633832B1 (fr) Vaccin antirabique avirulent
IT1233419B (it) Peptidi sintetici immunologicamente attivi utili per la preparazione di un vaccino antimalaria
ATE159758T1 (de) Azelluläre impfstoffe
CA2143187A1 (en) Anti-feline immunodeficiency virus (fiv) vaccines
DK224288A (da) Fremgangsmaade til fremstilling af peptidiske synthoner
EP0101677A4 (de) Antigene lineare peptidverbindungen.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties